tirzepatide and ssri glp-1 What are the considerations for using (a glucagon-like peptide-1 (GLP-1) receptor agonist) with fluvoxamine (a selective Tirzepatide and Antidepressants: Safe Use

On tirzepatide people are losing closer to 20% of their body weight and this is just the beginning. An evolving discussion around weight loss The introduction of this drug came at a complicated moment, when there has been significant backlash against the diet industry and more and more groups have been pushing to decouple body weight and health

Patients appreciate the significant weight loss they achieve and the improvement in related health conditions such as hypertension and diabetes

Two Phase 3 trials for AD109 with similar design to MARIPOSA are ongoing with topline results anticipated in mid-2025

A history of pancreatitis is generally considered a relative contraindication, meaning the risks likely outweigh the benefits

In most cases, initiation is best deferred until after discharge